258 related articles for article (PubMed ID: 22331493)
21. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
22. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
23. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
24. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
25. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
26. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
27. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro.
Du M; Qiu Q; Gruslin A; Gordon J; He M; Chan CC; Li D; Tsang BK
PLoS One; 2013; 8(1):e54572. PubMed ID: 23359652
[TBL] [Abstract][Full Text] [Related]
28. Arsenic accumulation decreased in metallothionein null Cisplatin-resistant cell lines.
Suzuki T; Ohata S; Togawa T; Himeno S; Tanabe S
J Toxicol Sci; 2007 Aug; 32(3):321-8. PubMed ID: 17785947
[TBL] [Abstract][Full Text] [Related]
29. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
[TBL] [Abstract][Full Text] [Related]
30. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
31. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.
Huang H; Chen AY; Ye X; Li B; Rojanasakul Y; Rankin GO; Chen YC
Int J Oncol; 2015 Oct; 47(4):1494-502. PubMed ID: 26315556
[TBL] [Abstract][Full Text] [Related]
32. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
34. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
35. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
36. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
37. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
38. Identification of p53 genetic suppressor elements which confer resistance to cisplatin.
Gallagher WM; Cairney M; Schott B; Roninson IB; Brown R
Oncogene; 1997 Jan; 14(2):185-93. PubMed ID: 9010220
[TBL] [Abstract][Full Text] [Related]
39. MDM2 sensitizes a human ovarian cancer cell line.
Mi RR; Ni H
Gynecol Oncol; 2003 Aug; 90(2):238-44. PubMed ID: 12893182
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
